Biological and Pharmacological Activities Of Squalene In Acute Myocardial Infarctio

Phase 2

Recruiting

• Conditions: Condition 1: Acute myocardial infarction. Condition 2: Heart failure.; ST elevation (STEMI) myocardial infarction of anterior wall; Heart failure; I21.0

• Registration Number: IRCT20221021056258N1
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

Patients 18 to 80 years old
Patients who have been diagnosed with ST segment elevation myocardial infarction and have undergone successful vascularization with angioplasty in the vessel related to the infarct.
Ejection fraction less than forty percent in the field of acute Myocardial infarction

Exclusion Criteria

Ventricular arrhythmia
Congenital heart disease
Suspected or documented history of heart failure or decreased ejection fraction (EF) of the left ventricle
CABG candidate patients or previous CABG history
GFR less than 30
People with autoimmune diseases or connective tissue disease
People with cancer
Pregnant and lactating women
Psychiatric patients and people who cannot complete the one-month clinical follow-up during the study.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Ejection fraction. Timepoint: Patients undergo echocardiography in the first 24 hours before starting the drug and then after 30 days. Method of measurement: Echocardiography.

Secondary Outcome Measures

Name	Time	Method
Wall motion abnormality. Timepoint: Before starting the medicine and also thirty days after starting the medicine. Method of measurement: Echocardiography.;Diastolic dysfunction. Timepoint: Before starting the medicine and also thirty days after starting the medicine. Method of measurement: Echocardiography.;Pulmonary arterial pressure. Timepoint: Before starting the medicine and also thirty days after starting the medicine. Method of measurement: Echocardiography.;Valvular Dysfunction. Timepoint: Before starting the medicine and also thirty days after starting the medicine. Method of measurement: Echocardiography.;Laboratory factors such as complete blood cell count. Timepoint: Before starting the drug and after thirty days from the start of the drug. Method of measurement: Laboratory kit.